IL17A and sarcoma: Moreover, the ELISA assay found that anti-IL-17 therapy downregulated spinal CXCL1 expression in the animals undergoing peripheral nerve trauma and sarcoma implantation (p < 0.05, n = 4; Figure 5C,F).